/ PFE
/ Market Analysis
Pfizer Shares Fall as 2026 Outlook Reflects Weaker COVID-19 Drug Demand
Pfizer shares fell after the company issued weaker-than-expected 2026 guidance, citing lower demand for COVID-19 products and upcoming patent expirations.
December 16, 2025
Santa Claus Rally: 3 Discounted Stocks Heading into 2026
Pfizer’s comeback, Newmont’s resilience, and Utz’s growth positioning make them compelling candidates for year-end gains.
November 12, 2025
Pfizer Tops EPS Expectations in Q3 2025 Despite Revenue Decline
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.
November 04, 2025
From Defense to Pharma to Energy: Dividend Opportunities Across Sectors
Lockheed’s defense backlog, Pfizer’s biotech expansion, and Schlumberger’s energy contracts make for safe and potentially lucrative dividend plays heading into year-end.
October 06, 2025
Pfizer Shares Gain Amid Reports of Deal with the US Government
Pfizer stock climbed over 3% on news of an impending drug-pricing deal with the Trump administration.
September 30, 2025More from The Tokenist / PFE
Pfizer (PFE) Beats Expectations in Q2 2025, Raises EPS Guidance
August 05, 2025
Pfizer Reports Q1 2025: Revenue Down 8% y/y
April 29, 2025
Pfizer (NYSE: PFE) Reports Better than Expected Q4 Results
February 04, 2025
Pfizer Targets Up to $64B Revenue in 2025 Amid Strategic Cost Savings
December 17, 2024
Back to 
